The Australia ECMO Machines Market was valued at $7.7 Million in 2025 and projected to reach to $10.22 Million by 2030, representing a compound annual growth rate of 5.8%. Australia's ECMO machines market is positioned for steady growth through 2030, supported by the country's advanced healthcare infrastructure and increasing clinical adoption of extracorporeal membrane oxygenation technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's ECMO machines market is valued at USD 7.7 million in 2025, with projected growth to USD 10.22 million by 2030, reflecting a steady 5.8% CAGR driven by increasing adoption in tertiary healthcare centers.
Australia's robust healthcare system and investment in advanced cardiac support technologies are accelerating ECMO device adoption across major medical centers, particularly in cardiac and respiratory critical care units.
Leading Australian tertiary hospitals and specialized cardiac centers are primary adopters of ECMO technology, with significant penetration in major cities including Sydney, Melbourne, and Brisbane.
Rising prevalence of acute cardiac and respiratory failures, coupled with Australia's aging population and advanced medical capabilities, is fueling demand for extracorporeal membrane oxygenation support systems.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION (ECPR) (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.8% from 2025 to 2030 |
| Largest Segment | ADULT PATIENTS (Patient Type) |
| Market Size Base Year (Billions) | ~USD 0.65 (2025) |
| Revenue Forecast (Billions) | ~USD 0.86 (2030) |
| Segments Covered | Product, Type, Modality, Patient Type, Application, End User |
6 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 1.93 | 2 | 2.09 | 2.17 | 2.27 | 2.38 | 2.49 | 2.62 | 4.7 |
| HOSPITALS | 7.48 | 7.84 | 8.24 | 8.67 | 9.15 | 9.67 | 10.23 | 10.85 | 5.7 |
| SPECIALTY CLINICS | 1.28 | 1.32 | 1.36 | 1.4 | 1.45 | 1.5 | 1.56 | 1.63 | 3.7 |
| TOTAL | 10.68 | 11.16 | 11.69 | 12.25 | 12.87 | 13.55 | 14.29 | 15.1 | 5.3 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| GETINGE | Sweden | Public Company | Acute Care Therapies,Surgical Workflows,Life Science, |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio (incl. Diabetes), |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| FRESENIUS MEDICAL CARE AG | Germany | Public Company | Dialysis services (outpatient and in-hospital ESRD/acute),Dialysis machines, cyclers, and water treatment systems,Dialysis consumables and solutions, |
| LIVANOVA PLC | United Kingdom | Public Company | Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, perfusion tubing, cannula, services),Neuromodulation (VNS Therapy for epilepsy and depression, aura6000 development), |
| NIPRO | Japan | Public Company | Dialysis products and artificial organ-related devices,Injection and infusion products, hospital and diabetic products, functional products,Pharmaceutical-Related (CDMO for injectables and oral drugs, kit products), |
| WEIGAO GROUP CO., LTD. | China | Public Company | Medical Device Products (infusion, clinical nursing, perioperative, urinary, rehab, extracorporeal circulation),Orthopedic Products (spine, joint, trauma, sports medicine, bone repair, spinal endoscope),Pharma Packaging Products (prefilled systems, packaging consumables, automatic drug delivery), |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| MICROPORT SCIENTIFIC CORPORATION | China | Public Company | Cardiovascular Devices,Orthopedics Devices,Cardiac Rhythm Management, |
Getinge is a Swedish public company founded in 1904 that employs 11,754 people and operates in the medical technology sector.
Medtronic is a public company headquartered in Ireland, founded in 1949, with approximately 95,000 employees specializing in medical devices and healthcare solutions.
Terumo Corporation is a Japanese public company established in 1921 with 30,591 employees, operating in the medical device and healthcare industry.
Fresenius Medical Care AG is a German public company founded in 1996 with 108,165 employees, providing dialysis and renal care services globally.
LivaNova PLC is a United Kingdom-based public company founded in 2015 with 3,300 employees, focused on neuromodulation and cardiac surgery solutions.
Nipro is a Japanese public company established in 1947 with 38,593 employees, manufacturing medical devices and pharmaceutical products.
Weigao Group Co., Ltd. is a Chinese public company founded in 1988 with 13,307 employees, specializing in medical device manufacturing.
Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating across diagnostics, medical devices, nutrition, and pharmaceuticals.
MicroPort Scientific Corporation is a Chinese public company established in 1998 with 6,547 employees, developing and manufacturing medical devices.
Australia's ECMO machines market is estimated at USD 7.7 million in 2025.
Australia's ECMO machines market is projected to reach USD 10.22 million by 2030.
Australia's ECMO machines market is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2030.
Key drivers in Australia include an aging population, rising cardiovascular disease prevalence, increased ICU infrastructure investment, and improved reimbursement pathways for advanced cardiac support therapies.
Tertiary hospitals and major medical centers with advanced intensive care units (ICUs) in Australia are the primary users and adopters of ECMO machines.
The study involved major activities in estimating the current market size of the ECMO machines market. Exhaustive secondary research was done to collect information on the ECMO market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the ECMO market.
This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, Factiva, whitepapers, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the ECMO market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the ECMO market. Primary sources from the demand side included hospitals, academic & research institutions, specialty clinics, researchers, lab technicians, purchase managers, and stakeholders in corporate & government bodies.
The following is a breakdown of the primary respondents:
Note 1: C-level primaries include CEOs, COOs, and CTOs.
Note 2: Others include sales managers, marketing managers, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=< USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the ECMO market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The entire market was split into three segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at precise statistics for all segments.
Approach to derive the market size and estimate market growth.
Using secondary data from paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of ECMO machines and components. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
An ECMO machine acts as an artificial heart and lung for a patient whose heart or lungs cannot provide enough blood flow or oxygen into the blood. ECMO is used after other methods of supporting the heart and lungs do not work. The goal of ECMO is to let the heart and lungs recover while the patient is supported by the ECMO machine.
Full forecast, segment splits, and company analysis for all ECMO Machines Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report